OncoGenex Pharma net loss improves in Q4 and FY14

• OncoGenex Pharmaceuticals (OGXI -2.6%) Q4 results: Revenues: $5.7M (-33.7%); R&D Expense: $9.9M (-25.0%); SG&A: $2.7M (+12.5%); Operating Loss: ($6.7M) (+4.3%); Net Loss: ($5.7M) (+14.9%); Loss Per Share: ($0.26) (+42.2%).
• FY2014 results: Revenues: $27.1M (-9.4%); R&D Expense: $46.2M (-16.5%); SG&A: $10.6M (+7.1%); Operating Loss: ($29.5M) (+16.4%); Net Loss: ($26.2M) (+17.6%); Loss Per Share: ($1.45) (+33.2%); Quick Assets: $47.3M (+19.7%).
• No guidance given.